scispace - formally typeset
H

Huriye Seker-Cin

Researcher at German Cancer Research Center

Publications -  11
Citations -  3230

Huriye Seker-Cin is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Medulloblastoma & DNA methylation. The author has an hindex of 9, co-authored 9 publications receiving 2667 citations.

Papers
More filters
Journal ArticleDOI

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

David T.W. Jones, +82 more
- 01 Aug 2013 - 
TL;DR: Recurrent activating mutations in FGFR1 and PTPN11 and new NTRK2 fusion genes in non-cerebellar tumors and new BRAF-activating changes were observed, indicating that pilocytic astrocytoma is predominantly a single-pathway disease.
Journal ArticleDOI

Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

Marcel Kool, +86 more
- 17 Mar 2014 - 
TL;DR: Functional assays in different SHH-MB xenograft models demonstrated that SHh-MBs harboring a PTCH1 mutation were responsive to SMO inhibition, whereas tumors harboring an SUFU mutation or MYCN amplification were primarily resistant.
Journal ArticleDOI

Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas

TL;DR: It is shown that reduced H3K27me3 levels and DNA hypomethylation act in concert to activate gene expression in K27M mutant pHGGs, and it is demonstrated that this is caused by aberrant recruitment of the PRC2 complex to K 27M mutant H3.3.
Journal ArticleDOI

Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma

Paul A. Northcott, +79 more
- 24 Jul 2014 - 
TL;DR: GFI1 and GFI1B are identified as prominent medulloblastoma oncogenes and ‘enhancer hijacking’ is implicate as an efficient mechanism driving oncogene activation in a childhood cancer.
Journal ArticleDOI

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

Stephen C. Mack, +88 more
- 27 Feb 2014 - 
TL;DR: It is concluded that epigenetic modifiers are the first rational therapeutic candidates for this deadly malignancy, which is epigenetically deregulated but genetically bland.